Amawi Haneen, Abu Deiab Ghina'a I, A Aljabali Alaa A, Dua Kamal, Tambuwala Murtaza M
Faculty of Pharmacy, Department of Pharmacy Practice, Yarmouk University, Irbid-Jordan.
Faculty of Pharmacy, Department of Medicinal Chemistry & Pharmacognosy, Yarmouk University, Irbid-Jordan.
Ther Deliv. 2020 Apr;11(4):245-268. doi: 10.4155/tde-2020-0035. Epub 2020 May 12.
At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand.
在撰写本综述时，严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）已感染全球超过2355853名患者，并导致超过164656人死亡（截至2020年4月20日）。本综述通过考虑2003年流行的SARS-CoV的强大基因相似性，重点介绍了针对SARS-CoV-2的预防措施、可用的临床治疗方法以及疫苗开发的潜力。由于目前尚无可用疫苗，许多临床试验正在评估美国食品药品监督管理局（FDA）批准药物的重新用途。正在评估几种对SARS-CoV和中东呼吸综合征冠状病毒有活性的抗病毒药、抗疟药和免疫调节剂。特别是，羟氯喹、瑞德西韦、法匹拉韦、阿比多尔、托珠单抗和贝伐单抗已显示出有希望的结果。本综述的主要目的是概述这场大流行以及我们目前的状况。
